Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Orders Label Revisions for Actemra, Tagrisso, Olumiant and More
September 25, 2019
- Intussusception Cases within 21 Days after Rotavirus Vaccination Should Be Reported: MHLW Panels
September 25, 2019
- Japan Launches Panel to Discuss “Social Security for All Generations”
September 24, 2019
- Japan Approves Astellas’ HIF-PH Inhibitor, AbbVie’s Venclexta, Tecentriq’s Breast Cancer Use and More
September 24, 2019
- Japan Clears First Biosimilars for Nesp and Forteo, Second Rituxan, Avastin Follow-Ons Too
September 24, 2019
- MHLW Asks 15 Makers to Investigate Ranitidine, Nizatidine for Potential Carcinogen Contamination
September 20, 2019
- Sakigake Status Withdrawn for Aducanumab: MHLW
September 20, 2019
- Kobe Univ. Received Pilot Certification as APEC Training Center of Excellence
September 20, 2019
- Doctor, Payer Reps Stress Need for More Education about Biosimilars Before Introducing Premium for Their Use: Chuikyo
September 19, 2019
- MHLW Panel Backs Inclusion of Rotavirus Vaccines to Public Immunization Program
September 17, 2019
- Orphan Status Granted to Satralizumab, 2 Other Drugs
September 17, 2019
- Show Us Concrete Proposals for Drug Pricing Reform: Kyokai Kenpo Director to Pharma
September 13, 2019
- Chuikyo Agrees on Need to Look at More Examples to Craft Pricing Models for Cell & Gene Therapies
September 12, 2019
- Both Payer, Doctor Members Want to Expand Comparator PMP Removal Rule, but Mixed on Timing: Chuikyo
September 12, 2019
- Chuikyo Members Open to Post-Launch Premiums for Add’l Indications, but Call for Careful Application
September 12, 2019
- 9 Topics Presented towards 2020 Pricing Reform; Industry Hearing Slated for November-December: Chuikyo
September 12, 2019
- Katsunobu Kato Makes Comeback as Health Minister
September 11, 2019
- MHLW Vows to Redouble Efforts to Prevent Future Information Leaks
September 11, 2019
- RWD Use in Regulatory Submissions Could Start with Rare Diseases: PMDA Chief
September 10, 2019
- MOF Budget Examiner Sounds Alarm on “Protected” Market, Prods Speedy Transformation
September 10, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…